Home/Pipeline/ING-008

ING-008

Cardiometabolic (Obesity, MASH)

PreclinicalActive

Key Facts

Indication
Cardiometabolic (Obesity, MASH)
Phase
Preclinical
Status
Active
Company

About Innosphera Pharma

First‑in‑class oral GPR84 modulator for IPF with a lipid‑mimetic platform targeting fibrosis and metabolic disease.

View full company profile